TWA
BCLI

TCI Wealth Advisors’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

TCI Wealth Advisors’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-73
Closed -$3K – 1359
2016
Q3 		$3K Hold
73
– – ﹤0.01% 842
2016
Q2 		$3K Hold
73
– – ﹤0.01% 820
2016
Q1 		$3K Hold
73
– – ﹤0.01% 825
2015
Q4 		$3K Hold
73
– – ﹤0.01% 782
2015
Q3 		$3K Hold
73
– – ﹤0.01% 710
2015
Q2 		$4K Hold
73
– – ﹤0.01% 675
2015
Q1 		$5K Buy
+73
New +$4.62K ﹤0.01% 560

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

TCI Wealth Advisors's BCLI Position: Q4 2016 in Review

TCI Wealth Advisors sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2016, closing a stake of 73 shares — an estimated $3K sold.

TCI Wealth Advisors first reported a position in BCLI in Q1 2015 and held it in 7 quarters. The position peaked at $5K in Q1 2015. 27 funds tracked by Wall St. Rank hold BCLI as of Q4 2016.

  • TCI Wealth Advisors reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2016 after selling out during the quarter.
  • TCI Wealth Advisors sold 73 BRAINSTORM CELL THERAPUTC shares in Q4 2016, an estimated $3K.
  • TCI Wealth Advisors first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2015 and held it in 7 quarters.
  • TCI Wealth Advisors's BRAINSTORM CELL THERAPUTC position peaked at $5K in Q1 2015.
  • 27 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2016.

Based on TCI Wealth Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.